
    
      The purposes of this study are to evaluate the pharmacokinetics, and pharmacodynamics and
      safety of an experimental intravenous medication, N-Rephasin® SAL200 in healthy male.
      Participants will include 36 male volunteers. Participants will be grouped according to
      dosage of N-Rephasin® SAL200 including placebo (0 mg/kg). Study procedures include: check of
      vital signs, reporting any experienced side effects, physical examination including
      assessment of the cardiovascular system, and blood sample collection for monitoring of
      pharmacokinetics, pharmacodynamics and antibody production etc. Participants will be involved
      in study related procedures for up to 50 days after injection.
    
  